<DOC>
	<DOCNO>NCT02075541</DOCNO>
	<brief_summary>The purpose Phase II study ass safety , reactogenicity immunogenicity investigational Non-typeable Haemophilus influenzae ( NTHi ) vaccine patient moderate severe persistent airflow obstruction .</brief_summary>
	<brief_title>A Study Evaluate Safety , Reactogenicity Immunogenicity GlaxoSmithkline ( GSK ) Biologicals ' Investigational Vaccine GSK2838504A When Administered Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Persistent Airflow Obstruction .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female , include , 40 80 year age time first vaccination . Written inform consent obtain subject . Confirmed diagnosis COPD force expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) ratio ( FEV1/FVC ) &lt; 0.7 , AND FEV1 &lt; 80 % ≥ 30 % predict . Current former smoker cigarette smoke history ≥ 10 packyears . Stable COPD patient document history least 1 moderate severe acute exacerbation COPD within 12 month Screening . Regular sputum producer . Capable comply daily electronic Diary Card completion throughout study period , accord investigator 's judgement Visit 1 . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/ product . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Planned administration/ administration vaccine foreseen study protocol period start 30 day first dose end 30 day last dose vaccine , exception influenza pneumococcal vaccine may administer ≥ 15 day precede follow study vaccine dose . Previous vaccination vaccine contain NTHi antigen . Administration immunoglobulins blood product within 3 month precede first dose study vaccine plan administration study period . Chronic administration nonsteroid immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History immunemediated disease COPD . Administration systemic corticosteroid within 30 day Screening . Administration systemic antibiotic within 30 day Screening . Chronic use antibiotic prevention acute exacerbation COPD ( AECOPD ) . Receiving oxygen therapy . Planned lung transplantation . Planned/ underwent lung resection surgery . Diagnosis α1 antitrypsin deficiency underlie cause COPD . Diagnosed respiratory disorder COPD , chest Xray/ CT scan reveal evidence clinically significant abnormality believe due presence COPD . Subjects allergic rhinitis enrol . History reaction hypersensitivity likely exacerbate component vaccine and/ bronchodilator used spirometry assessment study . Contraindication spirometry test . Clinically significant abnormality haematology biochemistry parameter . Acute cardiac insufficiency . Malignancies within previous 5 year lymphoproliferative disorder . Any known disease condition likely cause death study period . Acute disease and/ fever time Screening . Fever define oral axillary temperature ≥ 37.5°C . The preferred route record temperature study oral . Subjects acute disease and/ fever time Screening may enrol later date enrolment still open . Subjects minor illness without fever may enrol discretion investigator . Pregnant lactate female . Current alcoholism and/or drug abuse . Other condition investigator judge may put safety subject risk study participation may interfere study finding . Planned move location complicate participation trial study end .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Observer-blind</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Safety</keyword>
</DOC>